IBSA, Institute Biochimique S.A., is a Swiss pharmaceutical company which operates in 10 therapeutic areas and in more than 90 countries. The company success is based on ground breaking patented pharmaceutical technologies.
Luca Crippa (Milan, 1973) is CEO and Managing Director of IBSA Italy, the most important subsidiary of IBSA group and the one where the Global Aesthetic business unit is managed.
Before entering IBSA, Luca worked for Bayer as Head of Global Cardio Aspirin Business and as Country Manager Croatia & Serbia; in 2015 he moved to Nestlé Health Science to be Country Manager for Italy & Malta and than he was promoted to VP Global Consumer Care Healthy Aging Business and VP Global e-Business at the Lausanne headquarter.
Luca has started his career working as scientist in genetic engineering at the Mario Negri Institute and in medicinal chemistry at Glaxo Smith Kline; he graduated in Chemistry at the Milan University and studied Business Administration at SDA Bocconi, at Insead and at the London Business School.
IBSA is interested in getting in contact with potential global partners for commercial collaborations, new product development and contract manufacturing.
If interested you may connect with Luca on Linked-in https://www.linkedin.com/in/lucacrippa/ or discover more at https://www.ibsagroup.com/therapeutic-areas/dermoaesthetic.html